Assenagon Asset Management S.A. Acquires 54,063 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Assenagon Asset Management S.A. grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) by 76.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 125,207 shares of the biopharmaceutical company’s stock after acquiring an additional 54,063 shares during the quarter. Assenagon Asset Management S.A. owned about 0.09% of Halozyme Therapeutics worth $4,628,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. West Tower Group LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $28,000. Bessemer Group Inc. raised its holdings in Halozyme Therapeutics by 366.5% during the 2nd quarter. Bessemer Group Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 634 shares during the period. Advisory Services Network LLC raised its holdings in Halozyme Therapeutics by 50.5% during the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 303 shares during the period. Belpointe Asset Management LLC raised its holdings in Halozyme Therapeutics by 42.0% during the 1st quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 366 shares during the period. Finally, Harbour Investments Inc. purchased a new stake in Halozyme Therapeutics during the 4th quarter valued at $51,000. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at $6,519,075.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HALO. JMP Securities restated a “market outperform” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. Benchmark restated a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a report on Friday, January 19th. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Morgan Stanley reduced their target price on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 26th. Finally, HC Wainwright increased their target price on Halozyme Therapeutics from $48.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.29.

Check Out Our Latest Stock Report on HALO

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $40.68 on Monday. The firm has a market cap of $5.17 billion, a P/E ratio of 19.28, a P/E/G ratio of 0.49 and a beta of 1.25. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $45.00. The stock’s fifty day moving average price is $38.07 and its 200-day moving average price is $37.72.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.33 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Stories

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.